Tirzepatide versus insulin lispro in type 2 diabetes: SURPASS-6 trial

被引：0
|
作者：
Clauss, R. Maria
机构：
来源：
DIABETOLOGIE UND STOFFWECHSEL | 2024年 / 19卷 / 01期
关键词：
D O I：
10.1055/a-2167-7589
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Wenn die Glukoseregulation bei Typ-2-Diabetes (T2D) unter oralen Antidiabetika inadaquat ist, kommt die parallele oder alternative Insulintherapie in Betracht. Innovative Medikamente wie der Glukagon-like Peptid-1-Rezeptor-Agonist (GLP-1 RA) Tirzepatid zielen darauf ab, die Insulinsekretion zu stimulieren, um die externe Insulinzufuhr zu begrenzen. Von klinischem Interesse ist auch die unter diesen Medikamenten beobachtete Gewichtsreduktion.
引用
收藏
页码：26 / 26
页数：1
相关论文
共 50 条
  • [1] Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes The SURPASS-6 Randomized Clinical Trial
    Rosenstock, Julio
    Frias, Juan P.
    Rodbard, Helena W.
    Tofe, Santiago
    Sears, Emmalee
    Huh, Ruth
    Lando, Laura Fernandez
    Patel, Hiren
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (17): : 1631 - 1640
  • [2] Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial ( vol 330, pg 1631, 2023)
    Rosentock, J.
    Frias, J. P.
    Rodbard, H. W.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2025,
  • [3] Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial (oct , 10.1001/jama.2023.20294 , 2023)
    Rosentock, J.
    Frias, J. P.
    Rodbard, H. W.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (19): : 1915 - 1915
  • [4] Tirzepatide improves health-related quality of life vs insulin lispro in poorly controlled basal insulin-treated adults with type 2 diabetes (SURPASS-6)
    Boye, K.
    Sapin, H.
    Poon, J. -L.
    Lando, L. Fernandez
    Huh, R.
    Wang, M.
    Patel, H.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S314 - S314
  • [5] Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6)
    Boye, Kristina Secnik
    Poon, Jiat Ling
    Lando, Laura Fernandez
    Sapin, Helene
    Huh, Ruth
    Wang, Mianbo
    Williamson, Suzanne
    Patel, Hiren
    DIABETES THERAPY, 2024, 15 (09) : 2039 - 2059
  • [6] Tirzepatide Improves HRQoL Compared with Insulin Lispro in Poorly Controlled Basal Insulin-Treated Adults with Long-Standing T2D (SURPASS-6)
    Boye, Kristina
    Sapin, Helene
    Poon, Jiat Ling
    Lando, Laura Fernandez
    Huh, Ruth
    Wang, Mianbo
    Patel, Hiren
    DIABETES, 2023, 72
  • [7] Efficacy and Safety of Tirzepatide in Type 2 Diabetes: The SURPASS Clinical Trial Program
    Finney, Denis
    Levine, Josh A.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2023, 142 : S20 - S20
  • [8] Efficacy and Safety of Tirzepatide in Type 2 Diabetes: The Surpass Clinical Trial Program
    Barros, Mike
    Levine, Joshua A.
    AMERICAN HEART JOURNAL, 2022, 254 : 241 - 242
  • [9] Tirzepatide in aggiunta a insulina basale nel trattamento del diabete tipo 2: risultati del trial SURPASS-6
    Federica De Luca
    Valerio Velardi
    Riccardo Candido
    Stella Bernardi
    L'Endocrinologo, 2024, 25 (2) : 252 - 253
  • [10] INSULIN LISPRO WITH CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IS SAFE AND EFFECTIVE IN PATIENTS WITH TYPE 2 DIABETES: A RANDOMIZED CROSSOVER TRIAL OF INSULIN LISPRO VERSUS INSULIN ASPART
    Thrasher, James
    Bhargava, Anuj
    Rees, Tina M.
    Wang, Tao
    Guzman, Cristina B.
    Glass, Leonard C.
    ENDOCRINE PRACTICE, 2015, 21 (03) : 247 - 257
12345